Demographics of the study population
| . | Transplants (N = 2628) . |
|---|---|
| Age, y | |
| Patient | |
| 0-19 | 642 (24%) |
| 20-39 | 861 (33%) |
| 40 and older | 1124 (43%) |
| Unknown | 1 (<1%) |
| Donor | |
| 18-19 | 14 (<1%) |
| 20-39 | 1535 (58%) |
| 40 and older | 893 (34%) |
| Unknown | 186 (7%) |
| Year of transplantation | |
| 1987-1994 | 349 (13%) |
| 1995-1999 | 661 (25%) |
| 2000-2003 | 681 (26%) |
| 2004-2009 | 937 (36%) |
| Patient-donor gender | |
| Male-male | 910 (35%) |
| Male-female | 608 (23%) |
| Female-male | 562 (21%) |
| Female-female | 547 (21%) |
| Unknown | 1 (<1%) |
| Disease/early, intermediate, late, or advanced, other or unknown, no.* | |
| Acute myeloid leukemia | 766 (29%)/216, 246, 296, 8 |
| Acute lymphoblastic leukemia | 479 (18%)/142, 221, 113, 3 |
| Chronic myeloid leukemia | 574 (22%)/385, 158, 31 |
| Myelodysplastic syndrome | 310 (12%)/67, 0, 131, 112 |
| Non-Hodgkin lymphoma | 150 (6%)/NA |
| Other malignancies | 51 (2%)/NA |
| Nonmalignancies | 185 (7%)/NA |
| Patient-donor serologic status for cytomegalovirus | |
| Negative-negative | 816 (31%) |
| Negative-positive | 799 (30%) |
| Positive-negative | 412 (16%) |
| Positive-positive | 556 (21%) |
| Unknown | 45 (2%) |
| Transplant type† | |
| Myeloablative | 2105 (80%) |
| Reduced-intensity/nonmyeloablative | 505 (19%) |
| Unknown | 18 (1%) |
| Source of cells | |
| Bone marrow | 1726 (66%) |
| Peripheral blood stem cells | 902 (34%) |
| GVHD prophylaxis | |
| Cyclosporine with or without other agents | 1244 (47%) |
| Tacrolimus with or without other agents | 896 (34%) |
| T-cell depletion | 329 (13%) |
| Other combinations | 151 (6%) |
| Missing | 8 (< 1%) |
| Karnofsky performance score (%) | |
| 0-80 | 643 (24%) |
| 90-100 | 1614 (61%) |
| Missing | 371 (14%) |
| Patient-donor HLA-DPB1 | |
| Matched | 187 (7%) |
| GVH mismatch | 187 (7%) |
| HVG mismatch | 154 (6%) |
| Bidirectional mismatch | 1025 (39%) |
| Missing | 1075 (41%) |
| Patient ethnicity | |
| Hispanic | 206 (8%) |
| Non-Hispanic‡ | |
| White | 2141 (81%) |
| African American | 139 (5%) |
| Asian/Pacific Islander | 56 (2%) |
| Native American | 10 (<1%) |
| Other | 5 (<1%) |
| Unknown | 71 (3%) |
| Donor ethnicity | |
| Hispanic | 159 (6%) |
| Non-Hispanic‡ | |
| White | 1834 (70%) |
| African American | 128 (5%) |
| Asian/Pacific Islander | 54 (2%) |
| Native American | 27 (1%) |
| Other | 57 (2%) |
| Unknown | 369 (14%) |
| HLA mismatching§ | |
| HLA-A | 658 (25%) |
| Allele | 226 |
| Antigen | 430 |
| Unknown | 2 |
| HLA-B | 351 (13%) |
| Allele | 241 |
| Antigen | 107 |
| Unknown | 3 |
| HLA-C | 1006 (38%) |
| Allele | 203 |
| Antigen | 802 |
| Unknown | 1 |
| HLA-DRB1 | 159 (6%) |
| Allele | 139 |
| Antigen | 19 |
| Unknown | 1 |
| HLA-DQB1 | 454 (17%) |
| Allele | 111 |
| Antigen | 343 |
| . | Transplants (N = 2628) . |
|---|---|
| Age, y | |
| Patient | |
| 0-19 | 642 (24%) |
| 20-39 | 861 (33%) |
| 40 and older | 1124 (43%) |
| Unknown | 1 (<1%) |
| Donor | |
| 18-19 | 14 (<1%) |
| 20-39 | 1535 (58%) |
| 40 and older | 893 (34%) |
| Unknown | 186 (7%) |
| Year of transplantation | |
| 1987-1994 | 349 (13%) |
| 1995-1999 | 661 (25%) |
| 2000-2003 | 681 (26%) |
| 2004-2009 | 937 (36%) |
| Patient-donor gender | |
| Male-male | 910 (35%) |
| Male-female | 608 (23%) |
| Female-male | 562 (21%) |
| Female-female | 547 (21%) |
| Unknown | 1 (<1%) |
| Disease/early, intermediate, late, or advanced, other or unknown, no.* | |
| Acute myeloid leukemia | 766 (29%)/216, 246, 296, 8 |
| Acute lymphoblastic leukemia | 479 (18%)/142, 221, 113, 3 |
| Chronic myeloid leukemia | 574 (22%)/385, 158, 31 |
| Myelodysplastic syndrome | 310 (12%)/67, 0, 131, 112 |
| Non-Hodgkin lymphoma | 150 (6%)/NA |
| Other malignancies | 51 (2%)/NA |
| Nonmalignancies | 185 (7%)/NA |
| Patient-donor serologic status for cytomegalovirus | |
| Negative-negative | 816 (31%) |
| Negative-positive | 799 (30%) |
| Positive-negative | 412 (16%) |
| Positive-positive | 556 (21%) |
| Unknown | 45 (2%) |
| Transplant type† | |
| Myeloablative | 2105 (80%) |
| Reduced-intensity/nonmyeloablative | 505 (19%) |
| Unknown | 18 (1%) |
| Source of cells | |
| Bone marrow | 1726 (66%) |
| Peripheral blood stem cells | 902 (34%) |
| GVHD prophylaxis | |
| Cyclosporine with or without other agents | 1244 (47%) |
| Tacrolimus with or without other agents | 896 (34%) |
| T-cell depletion | 329 (13%) |
| Other combinations | 151 (6%) |
| Missing | 8 (< 1%) |
| Karnofsky performance score (%) | |
| 0-80 | 643 (24%) |
| 90-100 | 1614 (61%) |
| Missing | 371 (14%) |
| Patient-donor HLA-DPB1 | |
| Matched | 187 (7%) |
| GVH mismatch | 187 (7%) |
| HVG mismatch | 154 (6%) |
| Bidirectional mismatch | 1025 (39%) |
| Missing | 1075 (41%) |
| Patient ethnicity | |
| Hispanic | 206 (8%) |
| Non-Hispanic‡ | |
| White | 2141 (81%) |
| African American | 139 (5%) |
| Asian/Pacific Islander | 56 (2%) |
| Native American | 10 (<1%) |
| Other | 5 (<1%) |
| Unknown | 71 (3%) |
| Donor ethnicity | |
| Hispanic | 159 (6%) |
| Non-Hispanic‡ | |
| White | 1834 (70%) |
| African American | 128 (5%) |
| Asian/Pacific Islander | 54 (2%) |
| Native American | 27 (1%) |
| Other | 57 (2%) |
| Unknown | 369 (14%) |
| HLA mismatching§ | |
| HLA-A | 658 (25%) |
| Allele | 226 |
| Antigen | 430 |
| Unknown | 2 |
| HLA-B | 351 (13%) |
| Allele | 241 |
| Antigen | 107 |
| Unknown | 3 |
| HLA-C | 1006 (38%) |
| Allele | 203 |
| Antigen | 802 |
| Unknown | 1 |
| HLA-DRB1 | 159 (6%) |
| Allele | 139 |
| Antigen | 19 |
| Unknown | 1 |
| HLA-DQB1 | 454 (17%) |
| Allele | 111 |
| Antigen | 343 |
Data are n (%). Patients received their transplant at the Fred Hutchinson Cancer Research Center (n = 548) or at 1 of 149 other centers in the Center for International Blood and Marrow Transplant Research network (n = 2080).
GVH, graft-versus-host; HVG, host-versus-graft; NA, not applicable.
Disease status before transplant is categorized as early (first complete remission [CR] of acute myeloid leukemia [AML] or acute lymphoblastic leukemia [ALL], first chronic phase [CP] of CML, refractory anemia [RA] or refractory anemia with ring sideroblasts of myelodysplastic syndrome [MDS]); intermediate (second or higher CR of AML or ALL, second or higher CP or accelerated phase of CML); late or advanced (primary induction failure or first or higher relapse of AML or ALL, blast phase [or blast crisis] of CML, MDS RA with excess blasts or excess blasts in transformation); other (mainly unnamed MDS) or unknown. Other malignancies included Hodgkin lymphoma, plasma cell disorder, multiple myeloma, breast cancer, other malignancies. Non-malignancies included severe aplastic anemia, Shwachman-Diamond anemia, Diamond-Blackfan anemia, Fanconi anemia, sickle cell disease, thalassemia, inherited abnormalities of erythrocyte differentiation or function, other immune system disorders, inherited abnormality of platelets, inherited disorder of metabolism, histiocytic disorders and other nonmalignancies.
Myeloablative conditioning regimens: cyclophosphamide (Cy) with total body irradiation (TBI) given as a single dose >500 cGY or as fractionated TBI >800 cGY total; CY/etoposide (VP16)/TBI; busulfan (BU)/CY; TBI ≥ 500 cGY single dose; TBI ≥800 cGY fractionated; melphalan >150 mg/m2; BU >9 mg/kg; BU/melphalan. Reduced intensity regimens: TBI <500 cGY single dose; TBI <800 cGY fractionated; melphalan ≤ 150 mg/m2; BU ≤9 mg/kg; carmustine (BCNU)/VP16/cytarabine/melphalan (BEAM); CY/BCNU/VP16 (CBV); VP16/CY. Nonmyeloblative regimens: TBI 200 cGY; fludarabine (FLU)/TBI 200 cGY; FLU/CY; FLU/cytosine arabinoside (ARA-C).
Definitions follow the US Office of Management and Budget classification.8
HLA allele and antigens were defined according to the official World Health Organization HLA Nomenclature.9 Following this nomenclature, 5 novel sequences identified in patients (A*02, A*03, B*39, B*40, and C*01) and 2 patient-donor mismatch combinations (HLA-DRB1*03:01/03:05 and HLA-B*40:08/40:11) could not be defined.